SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.74 HKD | +4.88% |
|
+16.23% | -44.75% |
| Sales 2024 * | 1.83B 253M 1.98B 20.27B | Sales 2025 * | 3.18B 438M 3.43B 35.1B | Capitalization | 23.07B 3.18B 24.92B 255B |
|---|---|---|---|---|---|
| Net income 2024 * | -1.72B -237M -1.86B -19B | Net income 2025 * | -801M -111M -865M -8.85B | EV / Sales 2024 * | 11.2 x |
| Net cash position 2024 * | 2.6B 359M 2.81B 28.73B | Net cash position 2025 * | 1.67B 230M 1.8B 18.45B | EV / Sales 2025 * | 6.74 x |
| P/E ratio 2024 * |
-5.72
x | P/E ratio 2025 * |
-9.71
x | Employees | 2,568 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Shanghai Junshi Biosciences Co., Ltd.
More press releases
More news
| 1 day | +4.88% | ||
| 1 week | +16.23% | ||
| Current month | +8.81% | ||
| 1 month | +8.70% | ||
| 3 months | -18.02% | ||
| 6 months | -40.00% | ||
| Current year | -44.75% |
1 week
9.17
11.14
1 month
9.1711.44
Current year
9.1719.60
1 year
9.1731.10
3 years
9.1786.70
5 years
9.1797.15
10 years
9.1797.15
| Managers | Title | Age | Since |
|---|---|---|---|
Jianjun Zou
CEO | Chief Executive Officer | 52 | 19/04/22 |
Zhuo Bing Zhang
FOU | Founder | 57 | 26/12/12 |
Cong Li
CEO | Chief Executive Officer | 60 | 21/12/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cong Li
CEO | Chief Executive Officer | 60 | 21/12/16 |
Yi Tang
BRD | Director/Board Member | 56 | 29/05/15 |
Jun Xiong
CHM | Chairman | 50 | 26/03/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.31% | 4 M€ | -27.92% | ||
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 31 M€ | +3.50% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 10.74 | +4.88% | 2,282,800 |
| 25/04/24 | 10.24 | +5.24% | 957,991 |
| 24/04/24 | 9.73 | +0.83% | 1,282,584 |
| 23/04/24 | 9.65 | +3.88% | 790,800 |
| 22/04/24 | 9.29 | +0.54% | 568,400 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
28/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.942
CNY
Average target price
22.5
CNY
Spread / Average Target
+126.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.75% | 3.18B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 1877 Stock
